 NEWTON, Mass., Nov. 12, 2020 PRNewswire -- Karyopharm Therapeutics Inc. Nasdaq: KPTI, a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the results of the Phase 3 BOSTON Bortezomib, Selinexor and Dexamethasone study evaluating XPOVIO... 